Synthetic cholinergic blocking agents – Glycopyrrolate MCQs With Answer

Synthetic cholinergic blocking agents – Glycopyrrolate MCQs With Answer

Glycopyrrolate is a synthetic antimuscarinic (cholinergic blocking) agent widely taught in B. Pharm pharmacology courses for its clinical importance in anesthesia, surgery, and symptomatic management of secretions. This quaternary ammonium compound selectively antagonizes muscarinic receptors, reducing salivation, bronchial and gastric secretions, and mitigating bradycardia without significant central nervous system effects. Key topics include mechanism of action, receptor selectivity, pharmacokinetics, clinical indications, adverse effects, drug interactions, and comparison with atropine and scopolamine. These MCQs cover conceptual understanding, clinical application, and exam-focused facts to help B. Pharm students master glycopyrrolate. Now let’s test your knowledge with 50 MCQs on this topic.

Q1. Which class best describes glycopyrrolate?

  • Beta-adrenergic blocker
  • Quaternary ammonium antimuscarinic
  • Tertiary amine cholinomimetic
  • Acetylcholinesterase inhibitor

Correct Answer: Quaternary ammonium antimuscarinic

Q2. The primary therapeutic effect of glycopyrrolate used in anesthesia is:

  • Bronchodilation via beta-2 stimulation
  • Reduction of gastrointestinal motility
  • Antisialogogue effect (reduction of salivation)
  • Sedation through central muscarinic blockade

Correct Answer: Antisialogogue effect (reduction of salivation)

Q3. Glycopyrrolate has limited central nervous system effects mainly because it is:

  • Rapidly metabolized in the brain
  • Highly lipid soluble
  • A quaternary ammonium compound that poorly crosses the blood-brain barrier
  • Acting only on nicotinic receptors

Correct Answer: A quaternary ammonium compound that poorly crosses the blood-brain barrier

Q4. Which muscarinic receptor subtype is most associated with cardiac slowing that glycopyrrolate can antagonize?

  • M1
  • M2
  • M3
  • M4

Correct Answer: M2

Q5. Glycopyrrolate is commonly co-administered with neostigmine during reversal of neuromuscular blockade to:

  • Enhance neostigmine’s cholinesterase inhibition
  • Prevent muscarinic side effects such as bradycardia and bronchial secretions
  • Increase neuromuscular block depth
  • Act as a sedative adjunct

Correct Answer: Prevent muscarinic side effects such as bradycardia and bronchial secretions

Q6. Compared with atropine, glycopyrrolate is less likely to cause:

  • Dry mouth
  • Tachycardia
  • CNS delirium and sedation
  • Pupil dilation

Correct Answer: CNS delirium and sedation

Q7. A major contraindication for glycopyrrolate use is:

  • Peptic ulcer disease
  • Narrow-angle glaucoma
  • Hypotension
  • Diabetes mellitus

Correct Answer: Narrow-angle glaucoma

Q8. Which adverse effect is most commonly observed with antimuscarinic therapy like glycopyrrolate?

  • Excessive salivation
  • Diarrhea
  • Dry mouth (xerostomia)
  • Hypersalivation

Correct Answer: Dry mouth (xerostomia)

Q9. Glycopyrrolate’s action at muscarinic receptors is best described as:

  • Partial agonist at M3 receptors
  • Competitive antagonist at muscarinic receptors
  • Irreversible antagonist of nicotinic receptors
  • Allosteric positive modulator

Correct Answer: Competitive antagonist at muscarinic receptors

Q10. Which statement about glycopyrrolate pharmacokinetics is correct?

  • It freely crosses the blood-brain barrier
  • It is a lipid-soluble tertiary amine
  • It has minimal central penetration due to its quaternary structure
  • It is converted to atropine in vivo

Correct Answer: It has minimal central penetration due to its quaternary structure

Q11. In which clinical situation is glycopyrrolate often used preoperatively?

  • To increase gastric acid secretion
  • As an antihypertensive
  • To reduce airway and oral secretions
  • To induce muscle relaxation

Correct Answer: To reduce airway and oral secretions

Q12. Glycopyrrolate differs from scopolamine primarily in that glycopyrrolate:

  • Has stronger central sedative effects
  • Is more likely to cross the placenta
  • Is less likely to produce central anticholinergic effects
  • Acts as an acetylcholinesterase inhibitor

Correct Answer: Is less likely to produce central anticholinergic effects

Q13. A pharmacological effect of glycopyrrolate on the eye is:

  • Miosis (pupil constriction)
  • Increased lacrimation
  • Mydriasis (pupil dilation) and impaired accommodation
  • Decreased intraocular pressure

Correct Answer: Mydriasis (pupil dilation) and impaired accommodation

Q14. Which organ system’s secretions are decreased by glycopyrrolate?

  • Pancreas, salivary glands, and bronchial glands
  • Adrenal medulla catecholamines
  • Hypothalamic releasing hormones
  • Renal glomerular filtration only

Correct Answer: Pancreas, salivary glands, and bronchial glands

Q15. Glycopyrrolate is least likely to be effective in treating which of the following?

  • Excessive salivation due to anesthesia
  • Organophosphate poisoning definitive treatment
  • Prevention of bradycardia during surgery
  • Reduction of bronchial secretions in intubation

Correct Answer: Organophosphate poisoning definitive treatment

Q16. The ability of glycopyrrolate to reduce vagal reflex bradycardia is primarily due to blockade of:

  • Adrenergic alpha-1 receptors
  • M2 muscarinic receptors in the heart
  • Nicotinic receptors at the neuromuscular junction
  • Beta-1 adrenergic receptors

Correct Answer: M2 muscarinic receptors in the heart

Q17. Which patient condition requires caution when prescribing glycopyrrolate?

  • Chronic dry mouth
  • Benign prostatic hyperplasia with urinary retention
  • Seasonal allergies
  • Mild anemia

Correct Answer: Benign prostatic hyperplasia with urinary retention

Q18. Which statement about drug interactions with glycopyrrolate is true?

  • It potentiates cholinergic agonists
  • Co-administration with other anticholinergics increases anticholinergic adverse effects
  • It inactivates beta-blockers
  • It reduces opioid respiratory depression

Correct Answer: Co-administration with other anticholinergics increases anticholinergic adverse effects

Q19. In the context of reversal of neuromuscular blockade, glycopyrrolate is preferred over atropine because it:

  • Has a shorter duration of action causing fewer side effects
  • Causes more central sedation improving recovery
  • Does not cross BBB and produces fewer central side effects
  • Directly antagonizes depolarizing neuromuscular blockers

Correct Answer: Does not cross BBB and produces fewer central side effects

Q20. Which symptom would suggest glycopyrrolate overdose?

  • Excessive sweating
  • Severe dry mouth, hyperthermia, and tachycardia
  • Bradycardia and salivation
  • Profuse lacrimation and diarrhea

Correct Answer: Severe dry mouth, hyperthermia, and tachycardia

Q21. Glycopyrrolate’s inability to cross the placenta is mainly due to:

  • High lipid solubility and rapid ionization
  • Quaternary ammonium structure making it less lipid soluble
  • Strong binding to fetal tissue receptors
  • Active transport out of the fetus

Correct Answer: Quaternary ammonium structure making it less lipid soluble

Q22. Which of these is a legitimate clinical indication for glycopyrrolate?

  • Treatment of acute asthma attack as sole agent
  • Management of peptic ulcer as first-line therapy
  • Reduction of perioperative secretions and prevention of vagal reflexes
  • Long-term treatment of Alzheimer’s disease

Correct Answer: Reduction of perioperative secretions and prevention of vagal reflexes

Q23. Which route of administration is commonly used for glycopyrrolate in perioperative care?

  • Topical ocular drops only
  • Intravenous or intramuscular injection
  • Inhalation aerosol as first-line
  • Intrathecal injection

Correct Answer: Intravenous or intramuscular injection

Q24. Glycopyrrolate reduces gastric acid secretion primarily by blocking:

  • Histamine H2 receptors
  • M3 muscarinic receptors on parietal cells
  • Gastrin receptors directly
  • Proton pump activity

Correct Answer: M3 muscarinic receptors on parietal cells

Q25. Compared to atropine, glycopyrrolate has a:

  • Greater tendency to cause central nervous system side effects
  • Longer duration of peripheral antimuscarinic action with minimal CNS penetration
  • Stronger nicotinic receptor blockade
  • Higher ability to cross blood-brain barrier

Correct Answer: Longer duration of peripheral antimuscarinic action with minimal CNS penetration

Q26. Which physiological parameter is increased by glycopyrrolate due to vagal blockade?

  • Gastric motility
  • Pupillary constriction
  • Heart rate (tachycardia)
  • Salivation

Correct Answer: Heart rate (tachycardia)

Q27. Glycopyrrolate would most likely worsen which preexisting condition?

  • Chronic dry eyes
  • Narrow-angle glaucoma
  • Mild hypertension controlled with ACE inhibitors
  • Seasonal allergic rhinitis

Correct Answer: Narrow-angle glaucoma

Q28. The mechanism by which glycopyrrolate reduces bronchial secretions is through blockade of:

  • Beta-2 receptors on bronchial smooth muscle
  • M3 muscarinic receptors on bronchial glands
  • Nicotinic receptors at autonomic ganglia
  • Histamine H1 receptors

Correct Answer: M3 muscarinic receptors on bronchial glands

Q29. Which of the following is NOT a typical side effect of glycopyrrolate?

  • Urinary retention
  • Constipation
  • Excessive sweating
  • Blurred vision

Correct Answer: Excessive sweating

Q30. In organophosphate poisoning, glycopyrrolate can be used to:

  • Reactivate acetylcholinesterase
  • Reverse nicotinic skeletal muscle paralysis directly
  • Control muscarinic symptoms such as bronchorrhea and bradycardia
  • Neutralize organophosphate molecules

Correct Answer: Control muscarinic symptoms such as bronchorrhea and bradycardia

Q31. Glycopyrrolate’s action on sweat glands results in:

  • Increased sweating due to sympathetic stimulation
  • Decreased sweating (anhidrosis) since eccrine glands are muscarinic-innervated
  • No change because sweat glands are adrenergic
  • Excessive lacrimation instead of sweating

Correct Answer: Decreased sweating (anhidrosis) since eccrine glands are muscarinic-innervated

Q32. For B. Pharm students, which laboratory parameter would most likely be altered by glycopyrrolate?

  • Marked hyperkalemia
  • Significant change in liver enzymes
  • No direct specific routine lab marker; effects are clinical
  • Immediate increase in hemoglobin

Correct Answer: No direct specific routine lab marker; effects are clinical

Q33. Which statement about glycopyrrolate and pediatrics is true?

  • It readily crosses the immature blood-brain barrier causing strong CNS effects
  • It is never used in children
  • Dose adjustments are required and careful monitoring for anticholinergic effects is necessary
  • It is the primary long-term therapy for pediatric asthma

Correct Answer: Dose adjustments are required and careful monitoring for anticholinergic effects is necessary

Q34. A distinguishing chemical feature of glycopyrrolate is:

  • It is a tertiary amine derived from histamine
  • It contains a quaternary ammonium group that carries a permanent positive charge
  • It is a peptide-based antimuscarinic
  • It is structurally identical to atropine

Correct Answer: It contains a quaternary ammonium group that carries a permanent positive charge

Q35. Regarding duration of action, glycopyrrolate typically has:

  • A very brief action of a few minutes only
  • An intermediate to long peripheral antimuscarinic duration compared to atropine
  • Perpetual action requiring no redosing
  • Only topical ocular effects lasting 2 hours

Correct Answer: An intermediate to long peripheral antimuscarinic duration compared to atropine

Q36. Which clinical monitoring sign indicates effective vagal blockade after glycopyrrolate administration?

  • Reduction in systolic blood pressure by 30%
  • Increase in heart rate toward baseline or tachycardia
  • Excessive sweating and lacrimation
  • Onset of miosis

Correct Answer: Increase in heart rate toward baseline or tachycardia

Q37. In patients with myasthenia gravis, glycopyrrolate should be used with caution because it may:

  • Improve neuromuscular transmission dramatically
  • Exacerbate weakness by reducing acetylcholine availability at muscarinic receptors
  • Cause excessive salivation
  • Directly stimulate nicotinic receptors at the neuromuscular junction

Correct Answer: Exacerbate weakness by reducing acetylcholine availability at muscarinic receptors

Q38. Which symptom differentiates central anticholinergic syndrome from peripheral anticholinergic effects, and is less likely with glycopyrrolate?

  • Dry mouth
  • Confusion, agitation, hallucinations
  • Blurred vision
  • Urinary retention

Correct Answer: Confusion, agitation, hallucinations

Q39. Glycopyrrolate is listed as which type of agent in pharmacology classification?

  • Sympathomimetic agent
  • Antimuscarinic agent
  • Muscarinic agonist
  • Cholinesterase reactivator

Correct Answer: Antimuscarinic agent

Q40. Which monitoring precaution is important after giving glycopyrrolate to an elderly patient?

  • Monitor for hypoglycemia episodes
  • Observe for CNS effects despite low penetration and for urinary retention
  • No monitoring is required for anticholinergics
  • Expect marked diuresis

Correct Answer: Observe for CNS effects despite low penetration and for urinary retention

Q41. Which drug class, when combined with glycopyrrolate, would most likely cause an additive anticholinergic effect?

  • Beta-lactam antibiotics
  • Antihistamines with anticholinergic properties
  • Proton pump inhibitors
  • ACE inhibitors

Correct Answer: Antihistamines with anticholinergic properties

Q42. In dental or ENT premedication, glycopyrrolate is used primarily to:

  • Increase salivary flow
  • Reduce intraoperative secretions and improve visualization
  • Induce local anesthesia
  • Prevent bleeding via vasoconstriction

Correct Answer: Reduce intraoperative secretions and improve visualization

Q43. Which physiological reflex is attenuated by glycopyrrolate during surgical stimulation?

  • Baroreceptor reflex causing hypertension only
  • Vagal reflex causing bradycardia
  • Somatic withdrawal reflex
  • Renal autoregulatory reflex

Correct Answer: Vagal reflex causing bradycardia

Q44. Which of the following is a pharmacodynamic property of glycopyrrolate?

  • Enzyme induction of cytochrome P450
  • Competitive blockade of peripheral muscarinic receptors
  • Direct agonism at beta-2 receptors
  • Sequestration of acetylcholine in synaptic cleft

Correct Answer: Competitive blockade of peripheral muscarinic receptors

Q45. When teaching B. Pharm students, which exam-focused point about glycopyrrolate should be emphasized?

  • It is a potent nicotinic agonist used for smoking cessation
  • It is quaternary, so minimal CNS effects; commonly used as antisialagogue
  • It is primarily used as an antidepressant
  • It increases gastric motility and secretion

Correct Answer: It is quaternary, so minimal CNS effects; commonly used as antisialagogue

Q46. Which change in pulmonary physiology might glycopyrrolate produce?

  • Marked bronchoconstriction via M2 activation
  • Reduced bronchial secretions and decreased airway secretions
  • Enhanced mucociliary clearance
  • Increased pulmonary edema

Correct Answer: Reduced bronchial secretions and decreased airway secretions

Q47. Which statement best describes the onset of glycopyrrolate after IV administration?

  • Onset is typically rapid, within minutes, for systemic antimuscarinic effects
  • Onset is delayed for several days
  • It produces effects only after oral ingestion
  • It requires hepatic activation before effect

Correct Answer: Onset is typically rapid, within minutes, for systemic antimuscarinic effects

Q48. Which precaution is appropriate when glycopyrrolate is given to a patient with known tachyarrhythmia?

  • No precaution; it will reduce heart rate
  • Use cautiously because glycopyrrolate may cause or worsen tachycardia
  • Administer with a beta-agonist to prevent bradycardia
  • It will convert tachyarrhythmia to sinus rhythm reliably

Correct Answer: Use cautiously because glycopyrrolate may cause or worsen tachycardia

Q49. Which clinical scenario would favor glycopyrrolate over atropine?

  • Need for strong central anticholinergic sedation
  • When minimizing central nervous system side effects is important
  • Emergency treatment of severe bradycardia with rapid CNS penetration required
  • Treatment of Parkinson’s disease psychosis

Correct Answer: When minimizing central nervous system side effects is important

Q50. For exam preparation, which mnemonic or key point helps remember glycopyrrolate properties?

  • “Tertiary crosses BBB”
  • “Quaternary = Quiet CNS; coats secretions” meaning minimal CNS penetration and strong antisialagogue effect
  • “Inhibits acetylcholinesterase”
  • “Beta-blocker with anticholinergic actions”

Correct Answer: “Quaternary = Quiet CNS; coats secretions” meaning minimal CNS penetration and strong antisialagogue effect

Leave a Comment